boehringer glp-1 glp 1 EMPAGLIFLOZIN & RECEPTOR AGONISTS New Zepbound-Like GLP-1 Drug Leads

Glucagon-like Peptide 1 Receptor Agonists and Obesity Associated with Eating Disorders

2026: Acceleration and Market Transformation The coming year promises rapid evolution across innovation, policy, and market access

She also explained that rapid weight loss can come with downsides, including muscle loss, hair shedding, fatigue, and nutrient deficiencies

Discover effective strategies for maintaining muscle mass while taking injectable weight loss medications, including diet, exercise, and protein intake.

Learn how 2026 renewals will test plan design, compliance, and cost controland what conversations to start with clients before coverage questions hit.